SYT-510
Phase 2Small molecule
SYT-510 is one of 42 small molecule programs targeting Single Dose. It is currently in Phase 2.
2
Indications
2
Total Trials
2
Active Trials
41
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
26 competitors in Single Dose
#DrugCompanyPhaseTrials
1Namenda
AbbViePhase 2
Lioresal
NovartisPhase 2
Daliresp
AstraZenecaPhase 2
Cialis
Eli LillyPhase 1
Opdivo
Bristol-Myers SquibbPhase 1
Acoziborole
DDrugs for Neglected Diseases
Phase 3
LP-003
LLongbio Pharma
Phase 2
Psilocybin
COMPASS PathwaysPhase 1
SYT-510
SSynendos Therapeutics AG
Phase 2
Avodart
Akero TherapeuticsPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for SYT-510. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- SSynendos Therapeutics AG